A double blind, randomized, placebo-controlled, two-part study to investigate the pharmacokinetics, followed by efficacy and safety of GWP42006 as add-on therapy in patients with inadequately controlled focal seizures.
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2019
Price : $35 *
At a glance
- Drugs Cannabidivarin (Primary)
- Indications Partial epilepsies
- Focus Pharmacokinetics
- Sponsors GW Pharmaceuticals
- 05 Feb 2018 According to a GW Pharmaceuticals media release, data from this trial is expected in Q1 2018.
- 02 Jun 2016 Status changed from recruiting to completed.
- 06 Apr 2015 New source identified and integrated (United Kingdom Clinical Research Network: 17660)